Cited by 125Alzheimer's disease research and treatmentsProtease and Inhibitor MechanismsCholinesterase and Neurodegenerative Diseases

Seizure protein 6 and its homolog seizure 6-like protein are physiological substrates of BACE1 in neurons

Open access
Pigoni, Martina, Wanngren, Johanna, Kuhn, Peer-Hendrik, Munro, Kathryn M., Gunnersen, Jenny M., Takeshima, Hiroshi, Feederle, Regina, Voytyuk, Iryna +5 more·2016·Molecular Neurodegeneration

Abstract

BACKGROUND: The protease BACE1 (beta-site APP cleaving enzyme) is a major drug target in Alzheimer's disease. However, BACE1 therapeutic inhibition may cause unwanted adverse effects due to its additional functions in the nervous system, such as in myelination and neuronal connectivity. Additionally, recent proteomic studies investigating BACE1 inhibition in cell lines and cultured murine neurons identified a wider range of neuronal membrane proteins as potential BACE1 substrates, including seizure protein 6 (SEZ6) and its homolog SEZ6L. METHODS AND RESULTS: We generated antibodies against SEZ6 and SEZ6L and validated these proteins as BACE1 substrates in vitro and in vivo. Levels of the soluble, BACE1-cleaved ectodomain of both proteins (sSEZ6, sSEZ6L) were strongly reduced upon BACE1 inhibition in primary neurons and also in vivo in brains of BACE1-deficient mice. BACE1 inhibition increased neuronal surface levels of SEZ6 and SEZ6L as shown by cell surface biotinylation, demonstrating that BACE1 controls surface expression of both proteins. Moreover, mass spectrometric analysis revealed that the BACE1 cleavage site in SEZ6 is located in close proximity to the membrane, similar to the corresponding cleavage site in SEZ6L. Finally, an improved method was developed for the proteomic analysis of murine cerebrospinal fluid (CSF) and was applied to CSF from BACE-deficient mice. Hereby, SEZ6 and SEZ6L were validated as BACE1 substrates in vivo by strongly reduced levels in the CSF of BACE1-deficient mice. CONCLUSIONS: This study demonstrates that SEZ6 and SEZ6L are physiological BACE1 substrates in the murine brain and suggests that sSEZ6 and sSEZ6L levels in CSF are suitable markers to monitor BACE1 inhibition in mice.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13024-016-0134-z

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Besides APP, BACE1 has other substrates that may be important for synaptic plasticity and synaptic homeostasis.

    “Besides the amyloidogenic pathway, BACE1 has other substrates that may be important for synaptic plasticity and synaptic homeostasis.”

    From The β-Secretase BACE1 in Alzheimer’s Disease (2021) · cites this paper as [71]

  • In mouse brain, soluble SEZ6 is almost exclusively produced by BACE1.

    “In the mouse brain, soluble SEZ6 is almost exclusively produced by BACE1 (1,71).”

    From The β-Secretase BACE1 in Alzheimer’s Disease (2021) · cites this paper as [71]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Pigoni, M., Wanngren, J., Kuhn, P.-H., Munro, K. M., Gunnersen, J. M., Takeshima, H., Feederle, R., Voytyuk, I., De Strooper, B., Levasseur, M. D., Hrupka, B. J., Müller, S. A., & Lichtenthaler, S. F.
Affiliations
  • German Center for Neurodegenerative Diseases (DE)
  • TUM Klinikum (DE)
  • The University of Melbourne (AU)
  • Kyoto University (JP)
  • Janssen (Belgium) (BE)
Corresponding author
Lichtenthaler, Stefan F.
Venue
Molecular Neurodegeneration
Published
2016-10-05
Volume
11
Issue
1
Pages
67-67
ISSN
1750-1326 (ISSN-L)
OpenAlex
W2529572398
Cited by
125
References
57
Citations by year
2026: 9 · 2025: 13 · 2024: 9 · 2023: 13 · 2022: 19 · 2021: 19 · 2020: 13 · 2019: 12 · 2018: 9 · 2017: 7 · 2016: 2
FWCI
8.05
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Molecular Neurodegeneration (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
  • Lirias (KU Leuven) (submittedVersion, other-oa)
  • UCL Discovery (University College London) (submittedVersion)
  • mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
  • DZNE Pub (submittedVersion, other-oa)
  • PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion, cc-by)
Funders
  • BMBF (JPND-RiModFTD)
  • DFG (FOR2290)
  • Centers of Excellence in Neurodegeneration (CoEN)
  • Breuer Foundation (Alzheimer Research Price)
  • IWT (Agency for Innovation by Science and Technology)
  • Swedish Society for Medical Research
  • National Health and Medical Research Council (NHMRC)
  • German Academic Exchange Service (DAAD)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
  • Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
Keywords
BACE1, SEZ6, BACE1 inhibition, cerebrospinal fluid biomarkers, cell surface expression, Alzheimer's disease
MeSH terms
Animals, Brain, Immunohistochemistry, Nerve Tissue Proteins, Neurons, Mass Spectrometry, Substrate Specificity, Blotting, Western, Biomarkers, Aspartic Acid Endopeptidases, Mice, Knockout, Mice, Amyloid Precursor Protein Secretases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review